Angina Research Today is a free monthly online journal that collates and summarizes the latest research about Angina, including details on symptoms, treatment, causes, prevention, surgery.

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Ghofrani HA, Osterloh IH, Grimminger F

Medical Clinic II/V, Department of Internal Medicine, University Hospital Giessen and Marburg, GmbH, Klinikstrasse 36, 35392 Giessen, Germany. ardeschir.ghofrani@uglc.de

In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clinical medicine that have accompanied this journey and consider possible future indications for this versatile drug.

Published 2 August 2006 in Nat Rev Drug Discov, 5(8): 689-702.
Full-text of this article is available online (may require subscription).

© 2004-2008 Angina Research Today. All Rights Reserved.